Cost-effectiveness of lenacapavir for PrEP in Africa

By sjmartinez • September 24, 2024

Davey DJ, Jamieson L. Cost-effectiveness of lenacapavir for PrEP in Africa. Lancet HIV. 2024 Sep 20:S2352-3018(24)00242-X. doi: 10.1016/S2352-3018(24)00242-X. Epub ahead of print. PMID: 39312934.

Tags: Infectious Diseases, Publications

Transforming HIV prevention: the promise of long-acting preexposure prophylaxis in high HIV burden settings

Joseph Davey D, Dadan S, Wara N. Transforming HIV prevention: the promise of long-acting preexposure prophylaxis in high HIV burden settings. Curr Opin HIV AIDS.[...]

Lessons learned from COVID-19 to overcome challenges in conducting outpatient clinical trials to find safe and effective therapeutics for the next infectious pandemic

Oh MA, Currier J, Khan A, Mylonakis E, Newell M, Ignacio RB, Jilg N, Safdar B, Merck LH, Smith DM. Lessons learned from COVID-19 to[...]

ACTIV trials: cross-trial lessons learned for master protocol implementation

Keshtkar-Jahromi M, Adam SJ, Brar I, Chung LK, Currier JS, Daar ES, Davey VJ, Denning ET, Gelijns AC, Higgs ES, Jagannathan P, Javan AC, Jensen[...]